These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31214506)

  • 1. Is Repeat Transurethral Resection Always Needed in High-Grade T1 Bladder Cancer?
    Calò B; Chirico M; Fortunato F; Sanguedolce F; Carvalho-Dias E; Autorino R; Carrieri G; Cormio L
    Front Oncol; 2019; 9():465. PubMed ID: 31214506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
    Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
    World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
    Ferro M; Vartolomei MD; Cantiello F; Lucarelli G; Di Stasi SM; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdonà S; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Verze P; Battaglia M; Serretta V; Russo GI; Morgia G; Musi G; de Cobelli O; Mirone V; Shariat SF
    Urol Int; 2018; 101(1):7-15. PubMed ID: 29975950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study.
    Soria F; Rosazza M; Livoti S; Dutto D; Colucci F; Sylvester RJ; Shariat SF; Babjuk M; Palou J; Gontero P
    Eur Urol Focus; 2024 Jul; 10(4):648-653. PubMed ID: 37923633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
    Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
    Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of second transurethral resection for high-grade T1 bladder cancer.
    Hashine K; Ide T; Nakashima T; Hosokawa T; Ninomiya I; Teramoto N
    Urol Ann; 2016; 8(1):10-5. PubMed ID: 26834394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The impact of restaging transurethral resection on recurrence and progression free survival in patients with T1 high grade bladder cancer].
    Brun A; Koutlidis N; Thibault T; Escoffier A; Bardet F; Cormier L
    Prog Urol; 2023 Mar; 33(3):125-134. PubMed ID: 36604247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.
    Gontero P; Sylvester R; Pisano F; Joniau S; Oderda M; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Colombo R; Briganti A; Babjuk M; Soukup V; Malmström PU; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Vakarakis J; Bartoletti R; Dalbagni G; Shariat SF; Xylinas E; Karnes RJ; Palou J
    BJU Int; 2016 Jul; 118(1):44-52. PubMed ID: 26469362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer.
    Bishr M; Lattouf JB; Latour M; Saad F
    Can Urol Assoc J; 2014 May; 8(5-6):E306-10. PubMed ID: 24940455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Intravesical Bacilli Calmette-Guerin Therapy After Second Transurethral Resection in Stage Ta T1 High-Grade Bladder Cancer.
    Kimura Y; Honda M; Morizane S; Hikita K; Isoyama T; Ono K; Koumi T; Takahashi C; Takenaka A
    Yonago Acta Med; 2019 Jun; 62(2):191-197. PubMed ID: 31320823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.
    Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T
    BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.
    Shelley MD; Kynaston H; Court J; Wilt TJ; Coles B; Burgon K; Mason MD
    BJU Int; 2001 Aug; 88(3):209-16. PubMed ID: 11488731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis.
    Krajewski W; Nowak Ł; Poletajew S; Tukiendorf A; Moschini M; Mari A; Di Trapani E; Xylinas E; Kiełb P; Wełna M; Zdrojowy R
    J Endourol; 2020 Aug; 34(8):795-804. PubMed ID: 32336149
    [No Abstract]   [Full Text] [Related]  

  • 16. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
    Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
    BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis.
    Del Giudice F; Busetto GM; Gross MS; Maggi M; Sciarra A; Salciccia S; Ferro M; Sperduti I; Flammia S; Canale V; Chung BI; Conti SL; Eisenberg ML; Skinner EC; De Berardinis E
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3073-3080. PubMed ID: 33675400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
    Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
    BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
    Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
    Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.